The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026

Loading news article.

The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026 | WAPE

The FDA Accepts And Grants Priority Review To Astrazeneca's Supplemental Biologics License Application For Ultomiris (Ravulizumab) For Adults Patients With Immunoglobulin A Nephropathy; FDA Action Date Anticipated In Q4 Of 2026

Article summary

Related companies

Comments —